GSK Will Fold Antibody Developer Domantis Into Biopharmaceutical CEDD
GSK will pay $454 mil. to acquire Domantis’ technology for unconventional administration of monoclonal antibodies.
GSK will pay $454 mil. to acquire Domantis’ technology for unconventional administration of monoclonal antibodies.